Investor Presentaiton slide image

Investor Presentaiton

Important updates today Expanding Currently Launched Products Sotyktu: Impressive Ph2 SLE data supports Ph3 programs in SLE & SjS Abecma: - KarMMa-3 under regulatory review in triple class exposed population KarMMa-9 registrational trial in post-transplant MM initiating this year Subcutaneous nivolumab: - Potential to benefit patients into early 2030's with data anticipated this year Camzyos: Data suggests myosin inhibitors remodel the heart New Wave of NME LPA₁ Antagonist: Demonstrated compelling Ph2 PPF data and Ph3 studies initiating CD19 NEX T: - Ph 1 study initiated in severe, refractory lupus with promise to reset the immune system & expanding into other immunologic diseases BET Inhibitor (BMS-986158): Proof-of-concept data expected early next year GPRC5D CAR T: - Differentiated profile addressing unmet need post-BCMA targeting treatment; initiating pivotal trial next year alnuctamab: - - Initiating Ph3 trial in 2024 in MM iberdomide/mezigdomide: - Ph3 data expected in 2026 golcadomide: Initiating Ph3 trial in 2024 in 1L LBCL AR LDD: Significant opportunity in mCRPC with data expected early next year - Initiating pivotal trial in the next 18 months milvexian: Compelling rationale for Ph3 programs • • Early Assets to Watch BCMA X GPRC5D: Entering into POC soon BCL6 LDD: Novel oral degrader in lymphomas TIGIT Bispecific: - Differentiated IO; targeting TIGIT & CD96 DGK inhibitor: Potential transformational oral, dual inhibitor Anti-CCR8: Treg depleting mAb therapy with broad combination potential Advancing Neuro PoC trials in 2024: Anti-MTBR-Tau in Alzheimer's Disease elF2B Activator in ALS TYK2i CNS (pre-clinical): Moving into clinic soon, targeting MS MYK-224: Progressing into HFPEF O Increasing registrational assets from 6 to 12 in next 18 months ll Bristol Myers Squibb™ Increase INDs to at -10 per year Productivity о Increase to -20% POS from FIH to approval Achieve median -6.5 years from FIH to approval Not for Product Promotional Use 134
View entire presentation